Search Results - victor+velculescu

20 Results

Sort By:

Genetic Alterations in Medulloblastomas - MLL Genes as Targets for Diagnosis and Therapeutics

Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations,...

Published: 6/27/2024 | Inventor(s): Xiaosong Zhang, Hai Yan, Gregory Riggins, Victor Velculescu, Kenneth Kinzler, Darell Bigner, Nickolas Papadopoulos, Donald Parsons, Sian Jones, Rebecca Leary, Meng Li, Bert Vogelstein

Keywords(s): Biomarker, Brain Cancer, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Medulloblastoma, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Brain Cancer, Clinical and Disease Specializations > Oncology > Medulloblastoma

Genomic Drivers of Response to Immunotherapy

Unmet NeedTumor mutational burden (TMB) is a measurement of mutations carried by tumor cells and is but one emerging biomarker for some types of cancer, including non-small cell lung cancer. Currently, there is a lack of standardization for tumor mutational burden calculation and reporting. Different tests may report different measurements, and since...

Published: 6/28/2024 | Inventor(s): Valsamo Anagnostou, Victor Velculescu, Noushin Niknafs Kermani

Keywords(s): Biomarker, Clinical Diagnostics, In Vitro Diagnostics (Old), Prognostic Biomarker, Risk Stratification

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Computers, Electronics & Software > Algorithms

Discovery of human miRNAs and their evaluation with a Dicer KO line

Unmet NeedMicroRNAs (miRNAs) are a class of small noncoding RNAs that have important developmental and regulatory roles in multicellular organisms. There is considerable evidence to indicate that miRNAs and their biogenesis protein machinery (e.g., Dicer) are involved in the development of cancer.To identify novel miRNAs several approaches have been...

Published: 6/27/2024 | Inventor(s): Kenneth Kinzler, Victor Velculescu, Jordan Cummins, Bert Vogelstein

Keywords(s): Biomarker, Clinical Diagnostics, Diagnostic Biomarker, In Vitro Diagnostics

Category(s): Technology Classifications > Research Tools > Assays, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Technology Classifications > Research Tools

Biomarkers of Therapeutic Response in Ovarian Cancer

Unmet NeedOvarian cancer is the most common cause of death among gynecological cancers and is associated with poor outcomes and low overall survival rates. The current standard of care involves surgical resection of the solid tumor, followed by chemotherapy. This type of therapy has limited success among women with advanced disease, and often results...

Published: 6/27/2024 | Inventor(s): Victor Velculescu, Robert Scharpf, Eniko Papp, Dorothy Hallberg, Dennis Slamon, Gottfried Konecny

Keywords(s): Cancers, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Ovarian Cancer, Target-based Screening Tool

Category(s): Clinical and Disease Specializations > Oncology > Ovarian Cancer

Genetic Alterations Related to Anti-EGFR Therapeutic Response

Unmet Need:Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted therapies are monoclonal antibodies, which prevent epidermal growth factor receptor (EGFR) activation. Several studies have identified alterations in KRAS and other genes...

Published: 6/27/2024 | Inventor(s): Livio Trusolino, Andrea Bertotti, Victor Velculescu, Vilmos Adleff, Eniko Papp

Keywords(s): Biomarker, Cancers, Colorectal Cancer, Disease Indication, Pharmakodynamic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Oncology > Colorectal Cancer

Exomic sequences of ovarian clear cell carcinomas

Ovarian Clear Cell Carcinoma (OCCC) is an aggressive cancer that is generally resistant to therapy. To gain novel insights into the genetic origin of this tumor type, we determined the exomic sequences of eight tumors after immunoaffinity purification of neoplastic cells. Through comparison to normal cells from the same patients, we identified four...

Published: 6/27/2024 | Inventor(s): Sian Jones, Victor Velculescu, Kenneth Kinzler, Nickolas Papadopoulos, Ie-Ming Shih, Bert Vogelstein

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Ovarian Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Ovarian Cancer, Clinical and Disease Specializations > Women's Health, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics, Technology Classifications > Diagnostics > In Vitro Diagnostics, Clinical and Disease Specializations > Oncology

PALB2 Gene Mutations Identify Susceptibility to DNA Damaging Agents

PALB2 Gene Mutations Identify Susceptibility to DNA Damaging AgentsJHU Ref #: C10869Unmet NeedPancreatic cancer is predicted to be the second leading cause of cancer-related death by 2030 (Siegel et al., 2020). However, many patients present with advanced disease, and typical broad-spectrum chemotherapeutic treatments are often insufficient. Precision...

Published: 6/27/2024 | Inventor(s): Ralph Hruban, Bert Vogelstein, Kenneth Kinzler, Victor Velculescu, Scott Kern, Sian Jones, Michael Goggins, Manuel Hidalgo, Alison Klein, James Eshleman, Donald Parsons

Keywords(s): Biomarker, Clinical Diagnostics, In Vitro Diagnostics, Risk Stratification

Category(s): Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Precision Medicine Tools

Prognostic Markers in Pancreatic Cancer

TITLE: GENOMIC ALTERATIONS IN THE TUMOR AND CIRCULATION OF PANCREATIC CANCER PATIENTSCASE NUMBER: C13433UNMET NEEDSeveral genetic alterations have been identified in pancreatic cancers, including those in certain tumor suppressor genes and in oncogene. Although the discoveries of these genes and their pathways have provided important insights into...

Published: 6/27/2024 | Inventor(s): Victor Velculescu, Mark Sausen, Vilmos Adleff, Jillian Phallen

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer, Prognostic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostic Biomarkers, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

Generation of Human Cell Lines with Genetic Inactivation of PDPK1

C12018: Novel Human PDPK1, AKT1, and AKT2 Knock-out Cell Lines for Studying CancerNovelty: Development of modified human cancer cell lines with inactivated PDPK1 gene for studying colon cancer.Value Proposition: Modified human cell lines serve as useful research tools for studying the pathophysiology and cellular level differences between normal cells...

Published: 6/27/2024 | Inventor(s): Christine Gan, Nickolas Papadopoulos, Kajsa Ericson, Victor Velculescu, Kenneth Kinzler, Bert Vogelstein

Keywords(s): Basic Research Biomarker, Cell Lines, Discovery/Research Tools, Human Cell Lines, In Vitro Research Tool

Category(s): Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Human Cell Lines, Technology Classifications > Research Tools

DAXX/A TRX genes provide prognostic information in cancers

C11331: Methods and Biomarkers for the detection of Pancreatic Neuroendrocrine TumorsValue Proposition: • Mutations useful to accurately diagnose a patient with pancreatic neuroendocrine tumor • Novel prognostic indicators that predict clinical outcome • Genetic mutations identified that are useful to select and implement an appropriate...

Published: 6/27/2024 | Inventor(s): Nickolas Papadopoulos, Victor Velculescu, Luis Diaz, Yuchen Jiao, Kenneth Kinzler, Ralph Hruban, Bert Vogelstein

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Mechanism-of-action Biomarker, Pancreatic Cancer, Prognostic Biomarker, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics > Prognostics Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

1 2